Canada Biosimilars Proposal Requires Extra Studies To Show Substitutability
Substitution of a biosimilar for its reference brand product would not be automatic under the framework proposed by Health Canada for approving what it calls "subsequent entry biologics.
You may also be interested in...
The potential for biosimilars to lower Medicare and Medicaid drug spending could help catalyze support for a follow-on biologics bill this year, a Capitol Hill staffer predicted at the Food and Drug Law Institute's annual conference March 26
The European launch of biosimilar erythropoietin products has failed to impact European sales of Amgen's EPO products, EVP Worldwide Sales and Marketing George Morrow said during the company's third quarter earnings call Oct. 24
Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency